- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00986895
A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
January 13, 2017 updated by: Horizon Pharma Ireland, Ltd., Dublin Ireland
The purpose of this study is to determine the safety and tolerability of GT4P administered orally as a single dose, and twice daily for 7 consecutive days, to subjects with hepatic impairment with cirrhosis (Child-Pugh scores of A, B, or C) and to a gender matched and similar age control group with normal hepatic function.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kharkiv, Ukraine, 61057
- National University of Pharmacy
-
Kharkiv, Ukraine, 61128
- Department of General Surgery #2; Kharkiv State Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Subjects were required to fulfill the following criteria in order to participate in the study:
Screening:
- Males or females aged ≥ 18 years of age
- Able to provide written informed consent before any study-related procedures, and ability, in the opinion of the Investigator, to comply with all the requirements of the study
Classification to one of the following:
- current diagnosis of hepatic impairment with cirrhosis
- healthy subject
Subjects with hepatic impairment with cirrhosis were classifiable to one of the following groups:
- Child-Pugh score A
- Child-Pugh score B
- Child-Pugh score C
- Subjects with hepatic impairment with cirrhosis who were on a therapeutic regimen of lactulose must have been on a stable dose for ≥ 30 days prior to screening
- If female, a negative pregnancy test at screening and pre-dose on day 0, or a documented sterilization procedure; a female of child-bearing potential must have been using a medically approved birth control method and must have agreed to use the same method of contraception during the full course of the study (on pre-dose day 0 as well as at screening)
- Weight within the range of 60-100 kg (at screening and pre-dose on day 0)
- Willing to stop taking any medication that the Sponsor and the Investigator felt was not appropriate for use during the study, beginning 2 days before dosing and throughout the study
Exclusion Criteria:
Subjects who fulfilled any of the following criteria were excluded from the study:
Screening:
- Clinically significant history or evidence of cardiovascular, respiratory, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s), as determined by the Investigator
- Serum sodium < 120 mEq/L
- Serum creatinine ≥ 1.5 upper limit of normal
- Potassium ≤ 3.5 mEq/L
- Other laboratory values outside the normal range which were determined to be clinically significant by the Investigator
- Significant illness within the last 14 days
- Oral temperature > 38.5°C or < 36°C and/or a suspected site of active infection
- Inflammatory bowel disease or malabsorption defined with steatorrhea
- Active gastrointestinal bleeding, defined as melena, hematochezia, or hematemesis requiring hospitalization within the last 30 days
- Use of probenecid, valproate, or corticosteroids within the last 24 hours
- Use of any medication, other than those approved by the Sponsor and Investigator, in the last 48 hours
- History of seizures within the last 72 hours
- Positive drugs of abuse urine test
- Positive alcohol breath test
- Donation or loss of blood (500 mL or more) within the last 30 days
- Donation or loss of plasma within the last 7 days
- History of acquired immunodeficiency syndrome (AIDS) or determined human immunodeficiency virus (HIV) positive
- Hepatitis B or C (HBV; HCV) positive (healthy volunteers only)
- Use of any investigational drug within the last 30 days
- Known hypersensitivity to sodium phenylbutyrate or similar drugs
- Emergency hospitalization within the last 90 days
- Intake of alcohol in the last 7 days
Pre-dose (days 0 and 7):
- Significant illness or emergency hospitalization since the last study visit
- Oral temperature > 38.5°C or < 36°C and/or a suspected site of active infection
- Use of probenecid, valproate, or corticosteroids within the last 24 hours
- Use of any non-approved medication (by the Sponsor/Investigator) within the 48 hours before dosing
- History of seizures within the last 72 hours
- Positive drugs of abuse urine test
- Positive alcohol breath test
- Donation or loss of blood (500 mL or more) or plasma since the last study visit
- Use of any investigational drug since the last study visit
- Intake of alcohol in the last 7 days
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The rate of adverse event
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Igor Zupanets, MD, National University of Pharmacy
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Study Completion (Actual)
June 1, 2007
Study Registration Dates
First Submitted
September 15, 2009
First Submitted That Met QC Criteria
September 28, 2009
First Posted (Estimate)
September 30, 2009
Study Record Updates
Last Update Posted (Estimate)
January 16, 2017
Last Update Submitted That Met QC Criteria
January 13, 2017
Last Verified
September 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Liver Failure
- Hepatic Insufficiency
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Liver Diseases
- Genetic Diseases, Inborn
- Metabolism, Inborn Errors
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Amino Acid Metabolism, Inborn Errors
- Hepatic Encephalopathy
- Brain Diseases
- Urea Cycle Disorders, Inborn
Other Study ID Numbers
- UP 1204-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Encephalopathy
-
Jinnah Postgraduate Medical CentreNot yet recruitingHepatic Encephalopathy Stage 2 | Hepatic Encephalopathy Stage 3 | Hepatic Encephalopathy Stage 4Pakistan
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterInstituto Grifols, S.A.; McGuire Research InstituteCompletedHepatic Encephalopathy | Cirrhosis | Minimal Hepatic Encephalopathy | Covert Hepatic EncephalopathyUnited States
-
Sherief Abd-ElsalamTanta UniversityUnknownEncephalopathy, HepaticEgypt
-
Institute of Liver and Biliary Sciences, IndiaWithdrawnRefractory Hepatic EncephalopathyIndia
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Aga Khan UniversityUnknownEncephalopathy, Hepatic | Hepatocerebral Encephalopathy | Portal-Systemic Encephalopathy | Encephalopathy, HepatocerebralPakistan
-
Ain Shams UniversityCompletedMinimal Hepatic Encephalopathy
-
Mansoura UniversityCompletedMinimal Hepatic EncephalopathyEgypt
-
Shanghai Changzheng HospitalEnrolling by invitationHepatic Encephalopathy | Covert Hepatic EncephalopathyChina
-
Bausch Health Americas, Inc.CompletedOvert Hepatic EncephalopathyUnited States
Clinical Trials on HPN-100
-
Horizon Pharma Ireland, Ltd., Dublin IrelandCompletedHepatic Encephalopathy | CirrhosisUnited States
-
Horizon Pharma Ireland, Ltd., Dublin IrelandUcyclyd Pharma, Inc.Completed
-
Horizon Pharma Ireland, Ltd., Dublin IrelandCompletedDrug ToxicityUnited States
-
Horizon Pharma Ireland, Ltd., Dublin IrelandCompletedUrea Cycle DisordersUnited States, Canada
-
Horizon Therapeutics, LLCCompletedUrea Cycle DisordersUnited States, Canada
-
Horizon Pharma Ireland, Ltd., Dublin IrelandCompletedUrea Cycle DisordersUnited States, Canada
-
Hepanova Inc.UnknownNon-Alcoholic Steatohepatitis (NASH)United States
-
Horizon Pharma Ireland, Ltd., Dublin IrelandCompletedUrea Cycle DisordersUnited States
-
Horizon Pharma Ireland, Ltd., Dublin IrelandCompletedUrea Cycle DisordersUnited States
-
Horizon Therapeutics, LLCCompletedUrea Cycle DisorderUnited States, Canada